Ligand efficacy shifts a nuclear receptor conformational ensemble between transcriptionally active and repressive states
Abstract
Abstract Nuclear receptors (NRs) are thought to dynamically alternate between transcriptionally active and repressive conformations, which are stabilized upon ligand binding. Most NR ligand series exhibit limited bias, primarily consisting of transcriptionally active agonists or neutral antagonists, but not repressive inverse agonists—a limitation that restricts understanding of the functional NR conformational ensemble. Here, we report a NR ligand series for peroxisome proliferator-activated receptor gamma (PPARγ) that spans a pharmacological spectrum from repression (inverse agonism) to activation (agonism) where subtle structural modifications switch compound activity. While crystal structures provide snapshots of the fully repressive state, NMR spectroscopy and conformation-activity relationship analysis reveals that compounds within the series shift the PPARγ conformational ensemble between transcriptionally active and repressive conformations that are natively populated in the apo/ligand-free ensemble. Our findings reveal a molecular framework for minimal chemical modifications that enhance PPARγ inverse agonism and elucidate their influence on the dynamic PPARγ conformational ensemble.
Article Details
Authors (8)
Brian S. MacTavish
Di Zhu
School of Engineering, College of Systems & Society
Jinsai Shang
School of Basic Medical Sciences, State Key Laboratory of Respiratory Disease, Guangzhou National Laboratory
Qianzhen Shao
State Key Laboratory of Fluorine and Nitrogen Chemistry and Advanced Materials and Shanghai-Hong Kong Joint Laboratory in Chemical Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China
Yuanjun He
Zhongyue J. Yang
Department of Chemistry, Vanderbilt University
Theodore M. Kamenecka
Douglas J. Kojetin
Department of Integrative Structural and Computational Biology, Scripps Research, and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, University of Florida